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BACKGROUND: Blood vessels are a source of stem and progenitor cells, which likely contribute to a variety of vascular processes and diseases. Emerging 
concepts in this field could influence therapeutic approaches 
to diseases of blood vessels such as atherosclerosis.
CONTENT: Vascular Stem Cells (VSCs) field is only 
beginning to emerge, and thus, many issues regarding 
VSCs’s identity and function remain poorly understood. In 
fact, even after decades of intensive research, Mesenchymal 
Stem Cells (MSC), which is suggested to be VSCs, is still 
having many outstanding issues of its own. And, on top 
of this, likewise decades-long intensive pericyte research 
has not been able resolve the identity issue. While favors 
Adventitial Progenitor Cells  (APCs) over pericytes as the 
likely VSC candidate, it should be pointed out that currently 
the opposite view (i.e., pericytes as VSCs) is more prevalent, 
and many excellent reviews, including a recent one, have 
discussed this issue extensively.
SUMMARY: It has been postulated that, within the 
vasculature, APCs could differentiate into pericytes (CD34- 
CD31- CD140b+ SMA-), endothelial cells (CD34+ CD31+ 
CD140b- SMA-), and smooth muscle cells (SMCs) (CD34- 
CD31- CD140b- SMA+); and during tissue expansion or 
repair, APCs could also differentiate into tissue-specific cell 
types (e.g., muscle and fat) Thus, in vitro, APCs fulfill all 
criteria for being VSCs. Meanwhile, in vivo evidence is still 
limited and will require further investigation.
KEYWORDS: vascular stem cells, VSC, mesenchymal 
stem cells, MSC, endothelial progenitor cells, EPC, 
adventitial progenitor cells, APC
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LATAR BELAKANG: Pembuluh darah merupakan sumber sel punca dan sel progenitor, yang banyak berperan dalam berbagai proses dan penyakit 
vaskular. Konsep ini dapat mempengaruhi pendekatan 
terapi penyakit pembuluh darah seperti aterosklerosis.
ISI: Ketertarikan para ilmuwan akan Vascular Stem Cells 
(VSCs) baru akhir-akhir ini, sehingga pemahaman mengenai 
VSCs dan fungsinya masih sangat kurang. Penelitian 
Mesenchymal Stem Cells (MSCs) selama beberapa dekade 
terakhir, yang diduga adalah VSCs, belum mendapatkan 
titik temu. Penelitian yang intensif selama beberapa 
dekade mengenai pericyte juga tidak dapat memecahkan 
masalah ini. Artikel ini menggambarkan bahwa Adventitial 
Progenitor Cells  (APCs) merupakan kandidat kuat sebagai 
VSCs dibanding pericyte, dengan tidak mengesampingkan 
pendapat yang menyatakan bahwa VSCs adalah pericyte.
RINGKASAN: Telah diketahui bahwa di dalam pembuluh 
darah, APCs dapat berdiferensiasi menjadi pericyte (CD34- 
CD31- CD140b+ SMA-), sel endotel (CD34+ CD31+ 
CD140b- SMA-), dan sel otot polos (CD34- CD31- CD140b- 
SMA+); dan selama perkembangan atau perbaikan jaringan, 
APCs juga dapat berdiferensiasi menjadi tipe sel spesifik 
sesuai jaringan (misalnya, sel otot atau lemak). Jadi secara 
in vitro, APCs memenuhi kriteria sebagai VSCs. Namun 
secara in vivo, buktinya masih sedikit dan membutuhkan 
penelitian lebih lanjut.
KATA KUNCI: vascular stem cells, VSC, mesenchymal 
stem cells, MSC, endothelial progenitor cells, EPC, 
adventitial progenitor cells, APC
Abstract Abstrak
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The concept that stem cells reside in adult tissues, 
where they influence normal homeostasis and disease 
progression, has revolutionized paradigms of physiology 
and pathology. This is especially true for vascular system, 
which is associated with stem and progenitor cells in several 
ways.(1,2,3)
 Various cell types that make up vasculature, do 
not arise from a single embryonic source, and cells from 
multiple sources can ultimately acquire the same fate.(4,5) 
Given that blood vessels are found associated with virtually 
every organ and tissue in the body, it makes sense that 
local tissues provide precursor cells. Thus, vasculature has 
multiple cell types and does not arise homogeneously but is 
rather a mosaic of cells from different sources and locales. 
This diverse etiology may influence vascular function and 
disease propensity.(3)
 ‘‘Vascular stem cells’’ (VSCs) as a biomedical term 
first appeared more than 10 years ago, and their existence 
in humans and experimental animals was demonstrated 
another decade earlier. Granted, these cells remain poorly 
understood and not well known even in stem cell research 
field. VSCs is defined in this article as ‘‘cells that reside within 
the blood vessel wall and can differentiate into all of cell 
types that constitute a functional blood vessel.’’ Specifically, 
VSCs can differentiate into endothelial cells (ECs) and 
pericytes in capillary, and additionally, smooth muscle and 
adventitial cells in larger vessels.(6) Regulation of stem cell 
populations affects their recruitment, differentiation, spatial 
organization, and their coordination with host tissue. Loss 
and dysregulation of feedback control cause a variety of 
diseases that involve ectopic tissue formation, including 
atherosclerotic lesion formation and calcification, diabetic 
vasculopathies, and arteriovenous malformations.(7)
 This article overviews the spectrum of VSCs that 
have been documented in macro- and micro-vessels 
during developmental and adult life, and consideres the 
implications for a local, vascular wall stem cell niche(s) in 
the pathogenesis and treatment of cardiovascular and other 
diseases.
Stem Cells and Vasculature
Vasculature is a constantly adapting tissue, that penetrates 
every other organ in the body except cornea and cartilage. 
Consequently, vascular disease has the potential to affect all 
organs and tissues. Tissue repair and regeneration will also 
have to involve vasculature, where it may even be initiated 
or triggered. These features make vasculature itself an 
Introduction ideal site to place stem cells strategically in pools that can be expanded rapidly to respond to injury and disease. This 
hypothesis suggests an interesting interface, where stem cell 
biology could greatly contribute to our understanding in the 
role of stem cells in vascular disease.(7)
 Blood vessels are composed of ECs that provide the 
inner (luminal) surface of the vessel in contact with blood, 
and mural cells that interact with the outer (abluminal) 
surface of ECs. Mural cells most often are pericytes, and 
the vessel wall of the vast majority of vessels in body, 
which comprise microcirculation, consists simply of 
ECs surrounded by pericytes. Larger vessels, especially 
arterioles, arteries and veins, are invested with SMCs and 
elastic fibers that provide contractility, and larger arteries 
and veins also have an organized structure of fibroblasts that 
produce collagen.(3) The diverse embryonic sources of both 
ECs and mural cells argue against a single type of VSCs, 
analogous to the hematopoietic stem cell, which would both 
self-renew and contribute to all vascular lineages. It can 
also be argued that there is no need for a VSC, as once ECs 
differentiate they retain the capacity to proliferate and form 
new vessels via sprouting angiogenesis, and mesenchymal 
cells capable of recruitment to mural lineages reside in most 
local environments. However, both vascular compartments-
endothelial and mural are associated with stem cells, 
progenitor cells or both during development.(8-10)
 Vascular structures are unique. They are expected to 
take up little space and at the same time perfuse and deliver 
nutrients to all locations in the body. Thus, they will have to 
show inventiveness in penetrating organs and adapting to 
the spatial structure of each organ. Considering the stringent 
space restrictions, it is an interesting problem how stem 
cells are provided locally for repair or for the development 
of new vessels. Strategies will be needed to keep the number 
of progenitor cells low, yet keep them available for rapid 
mobilization and expansion.(11,12) Stem cell pools may be 
one way that the vasculature responds to these requirements. 
Stem cells are often found near basement membrane, 
which has suggested the existence of so-called ‘‘niches’’ or 
specialized microenvironments for stem cells.(13,14)
 A cell population in proximity to the basement 
membrane would be perfectly located to supply both ECs 
and smooth muscle cells (SMCs) progenitor cells, enabling 
quick regeneration. The origin of such progenitor cells 
would include resident vascular as well as circulating stem 
cells. Resident stem cells may be reserved and positioned 
during development(15), whereas circulating stem cells, 
mainly derived from the bone marrow (BM) (16,17), may be 
rapidly mobilized from the circulation and modified by the 
vascular context. There is dramatic evidence of multipotent 
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cells in the vasculature, especially in vascular calcification 
and ectopic bone formation.(18,19) Multiple studies have 
demonstrated that vascular mesenchymal cells, including 
microvascular pericytes, so-called calcifying vascular 
cells and SMCs, undergo osteochondrogenic lineage 
differentiation spontaneously or under special conditions 
such as hyperphosphatemia.(18,20)
 In recent times, these traditional views of 
vascular biology have been revised by the discovery of 
immature stem/progenitor cell populations, relevant to 
endothelial(21,22), smooth muscle(23-25), myeloid(26) 
and multipotent mesenchymal lineage(27) that have been 
shown to participate in postnatal vasculogenesis and 
vascular wall remodeling. An increasing body of evidence 
points to the existence of these different progenitor cell 
types within embryonic, fetal and adult vessel walls, where 
they may reside either constitutively or appear as a result 
of circulating migration.(2) Thus, the stem cell biologist 
could greatly support vascular biology with knowledge of 
how to reverse terminal differentiation toward more stem 
cell-like characteristics, and the relation between stages of 
differentiation and the patterning of tissues, all central in 
vascular regeneration and disease.
Angiogenesis and “Vasculogenic Zone”
Development of vasculature and its subsequent homeostasis 
are integral components of embryogenesis, fetal 
organogenesis, maintenance of health and normal function 
of adult tissues. In embryonic life, emergence of ancestral 
stem/progenitor cells for both ECs and hematopoietic cells 
gives rise to the formation of blood vessels, which are then 
stabilized by  incorporation of peri-ECs and stromal elements.
(28) New blood vessel formation (neovascularization) 
also continues in adults and is a key contributor to both 
physiological and pathological processes, including tissue 
ischemia, repair and regeneration, atherosclerosis, tumor 
growth and metastasis.(1)
 Postnatal vascular wall comprises three concentric 
layers consisting of a limited number of cell types. Tunica 
intima has an EC lining which interfaces with blood,  media 
contains several layers of SMCs, and adventitia is made up 
of stromal and adipose tissue, along with the vasa and nerva 
vasorum. Disruption of vessel wall integrity is associated 
with pathogenesis of various disease processes, including 
atherosclerosis, aneurysm formation, vasculitis, allograft 
vasculopathy and post-intervention restenosis, which in 
turn may occlude tissue blood supply, leading to ischemia or 
infarction.(2) Up until the last decade, it was widely believed 
that cellular elements of adult vessel wall are terminally 
differentiated and thus relatively quiescent. Angiogenesis, 
defined as the formation of new blood vessels from pre-
existing ECs, was considered to be the only mechanism by 
which neovascularization occurred after birth.(1)
 Main steps of this process comprise ECs migration, 
proliferation and tube formation. Accumulating data 
indicate a role for circulating endothelial precursor cells and/
or BM-derived endothelial precursor cells involved in the 
new blood vessel formation(21,29-32), a process defined as 
postnatal vasculogenesis. More recent data suggest a role for 
tissue-bound precursor cells as source of vascular cells and 
concomitantly accumulating macrophages during collateral 
vessel growth.(33) The existence of local tissue-bound adult 
precursor cells has been reported for different organs(34,35), 
but not yet for the wall of adult blood vessels(36). Our data 
suggest the existence of a ‘vasculogenic zone’ in the adult 
human vascular wall that is, to our knowledge, the first 
reported location for endothelial progenitor cells (EPCs) 
outside the BM, which may serve as a source for progenitor 
cells for postnatal vasculogenesis, contributing to tumor 
vascularization and local immune response.(26)
 The local activation and migration of vascular wall 
resident progenitor cells (VW-PCs) is believed to contribute 
to cell turnover during physiologic and pathogenic vascular 
remodeling and neovascularization, while there may also be 
dynamic, bidirectional exchange of progenitor cells between 
the vessel wall and peripheral circulation throughout adult 
life.(2)
Atherosclerosis and Diabetic Complications
Many studies in animals and in humans have demonstrated 
that various lineages of BM-derived cells in the circulation 
infiltrate vascular lesions. In addition to vascular progenitor 
cells, new subsets of immune cells are emerging as 
important effectors and regulators of immune responses. 
Moreover, recent studies have unraveled dynamic plasticity 
in their phenotypes and functions.(37) Recent studies have 
demonstrated that BM cells also may serve as sources of 
vascular cell lineages, including EPCs and smooth muscle 
progenitor cells (SMPCs).(21,38) Although these vascular 
progenitors originally had been thought to differentiate into 
mature and functional endothelial and SMCs in physiological 
and pathological settings(21,37), subsequent studies have 
reported conflicting results(37). Therefore, it is still unclear 
whether these cells acquire definitive endothelial and SMC 
identities. Accordingly, their functional contributions to 
atherogenesis are still undergoing debate. The development 
of vascular diseases, such as intimal hyperplasia and 
atherosclerosis, involves proliferation and migration of 
vascular cells.(39-42) Vascular SMCs are the predominant 
cell type in the tunica media of the blood vessel wall. Studies 
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from many laboratories have shown that cultured SMCs and 
SMCs in the neointima “loose” the expression of smooth 
muscle myosin heavy chain (SM-MHC), a marker of 
contractile SMCs, and become proliferative and synthetic.
(43-48) A widely accepted explanation is that SMCs have 
phenotypic plasticity and that mature or contractile SMCs 
can de-differentiate into proliferative and synthetic SMCs 
4.(49-51) However, this de-differentiation process has not 
been directly demonstrated by tracking the fate of mature or 
contractile SMCs.
 Tang, et al. provide evidence that challenges this 
theory. They identify a new type of multipotent vascular 
stem cell (MVSC) in blood vessel wall. MVSCs express 
markers including Sox17, Sox10 and S100β, are cloneable, 
have telomerase activity, and can differentiate into neural 
cells and MSC-like cells that subsequently differentiate 
into SMCs.(52) Upon vascular injuries, MVSCs, instead of 
SMCs, become proliferative, and MVSCs can differentiate 
into SMCs and chondrogenic cells, thus contributing to 
vascular remodeling and neointimal hyperplasia. These 
findings support a new hypothesis that the differentiation 
of MVSCs, rather than the de-differentiation of SMCs, 
contributes to vascular remodeling and diseases.(52) These 
findings provide unprecedented insight into the role of stem 
cells in vascular diseases and remodeling, which suggests 
that vascular diseases are stem cell diseases. These findings 
may have transformative impact on vascular biology and 
diseases, and may lead to new therapies by using VSCs as a 
therapeutic target.
 Angiogenesis, the predominant form of 
neovascularization in atherosclerosis, is mediated by ECs 
sprouting from postcapillary venules, leading primarily to 
new capillaries.(53) The molecular mechanisms responsible 
for neovessel formation are related predominantly to hypoxia. 
Figure 1. Mural distribution of VW-PCs.(2) 
(Adapted with permission from Springerlink).
Figure 2. Hypothetical scheme of the 
‘vasculogenic zone’.(21) (Adapted 
with permission from The Company of 
Biologist Ltd).
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More recently, hypoxia-independent pathways have also 
been described, mediated primarily by inflammation and 
activation of the toll-like receptor.(54)
 On the basis of the aforementioned observations, it is 
reasonable to develop the following hypothesis: Adventitial 
-derived vasa vasorum neovascularization develops under 
the trigger of oxidized low-density lipoprotein deposits in 
the intima, mediated by hypoxia and toll-like receptors. 
Such neovessels may contribute to the removal of intimal 
fat when the concentration of low-density lipoprotein is 
lower in the neovessel circulation than in the intima (low-
density lipoprotein concentration gradient). However, 
extravasation of red blood cells (RBCs) from leaky 
neovessels attracts macrophages to the field, both at the 
intima-media junction and the shoulders of the plaque. 
Macrophage erythrophagocitosis leads to cell activation at 
these crucial sites of the plaque. Then macrophage-derived 
matrix metalloproteinase secretion leads to rupture of the 
internal elastic lamina(55) and fibrous cap collagenolysis, 
precipitating plaque rupture and thrombosis(56).
 Diabetes mellitus, through the impairment of vascular 
stem and progenitor cells entails a defective repair of the 
injured endothelium.(58) To stop the progression of these 
complications and to repair the damage, we would need 
to either replace the damaged ECs or create brand new 
vascular networks. Considering mounting evidence of stem/ 
progenitor cells in various tissues including the blood vessel 
wall(50), we can speculate that the reason diabetic patients 
exhibit impaired repair mechanisms is because these stem/
progenitor cells are also affected(60). Ideally, it would be 
one cell type or a subpopulation that can produce both 
ECs and the supportive perivascular cells. The notion of a 
specific VSC able to produce mature/functional cells of the 
blood vessels is slowly gaining momentum.
 The exact identity of the VSCs is still not clear. There 
is ample evidence that these VSCs are found in the BM and 
Figure 3. Schematic illustration of the spontaneous 
differentiation of MVSCs and the differentiation potential 
of the cells at different stages.(52) (Adapted with permission 
from Nature Publishing Group).
circulation and are quite distinct from hematopoietic stem 
cells. Selection of cluster of differentiation (CD)133+ cells 
from the circulation purifies a population(s) of cells that 
under different culture conditions, will produce lineage-
restricted EPCs and mesenchymal/mesodermal progenitor 
cells (MPCs).(61-65) The vascular changes that occur in 
diabetic complications highlighting some of the common 
features, the key findings that illustrate an important role of 
VSCs in the pathogenesis of chronic diabetic complications, 
and provide mechanisms by which these cells can be used 
for therapy.
What are Vascular Stem Cells?
MSCs exist in most adult tissues and have been located 
near or within blood vessels. Although ‘‘perivascular’’ has 
been commonly used to describe such locations, increasing 
evidence points at the vessel wall as the exact location. 
Thus, VSCs is recommended as a more accurate term for 
MSCs. Furthermore, 2 cell populations, namely pericytes 
and Advential Progenitor Cells (APCs), are the likely VSCs. 
The pericyte evidence relies on the so-called pericyte-
specific markers, but none of these markers is pericyte 
specific. In addition, pericytes appear to be too functionally 
diverse and sophisticated to have a large differentiation 
capacity. On the other hand, APCs are more naıve 
functionally and, therefore, more akin to being VSCs. These 
cells spontaneously in vitro-differentiate into pericytes, and 
can be induced to differentiate into vascular cells (ECs and 
SMCs) and mesenchymal cells (e.g., bone, cartilage, and 
fat).(6)
 While EPCs are defined as originating from BM and 
circulating in the blood, ‘‘true’’ VSCs (as defined earlier, 
in introduction) are expected to reside within the blood 
vessel wall. At this location, 3 distinct cell types exist: 
ECs and pericytes in capillaries, and additionally, SMCs 
in larger vessels. In addition, a mixed population of cells 
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(macrophages, dendritic cells, fibroblasts, and progenitor 
cells) resides in the adventitia.(66,67) The possibilities 
for these vessel wall cells to be stem or progenitor cells 
have been reviewed, for example, in these recent articles.
(2,3,7,15,66-72) In particular, pericytes and APCs have 
emerged as the most plausible VSCs.
 Pericytes, the mural cells of blood microvessels, 
have recently come into focus as regulators of vascular 
morphogenesis and function during development, 
cardiovascular homeostasis and disease. Pericytes are 
implicated in the development of diabetic retinopathy 
and tissue fibrosis, and they are potential stromal targets 
for cancer therapy. Some pericytes are probably MSCs or 
progenitor cells, which give rise to adipocytes, cartilage, 
bone and muscle. However, there is still confusion about the 
identity, ontogeny, and progeny of pericytes.(73) Pericytes 
and ECs are intimately connected by tight and gap junctions, 
and each pericyte may be in contact with several ECs via 
elongated processes wrapping around and along the blood 
vessel.(74,75) In larger vessels, pericytes may be observed 
not only as sub-ECs in the inner intimal layer, but also in the 
media and adventitia associated with the vasa vasorum.(76)
 Evidence is accumulating to suggest a close relationship 
between MSCs and pericytes. Conceivably, given that 
MSCs (and pericytes) isolated from disparate tissues 
exhibit subtle variability in differentiation capability, it is 
possible that MSCs are ubiquitous perivascular progenitor 
cells distributed throughout the body, but with a degree of 
lineage allegiance to their host tissue.(68) Conventional 
views of the tunica adventitia as a poorly organized layer 
of vessel wall composed of fibroblasts, connective tissue, 
and perivascular nerves are undergoing revision. Recent 
studies suggest that the adventitia has properties of a 
stem/progenitor cell niche in the artery wall that may be 
poised to respond to arterial injury. It is also a major site 
of immune surveillance and inflammatory cell trafficking 
and harbors a dynamic microvasculature, the vasa vasorum, 
that maintains the medial layer and provides an important 
gateway for macrophage and leukocyte migration into the 
intima. In addition, the adventitia is in contact with tissue 
that surrounds the vessel and may actively participate in 
exchange of signals and cells between the vessel wall and 
the tissue in which it resides.(30)
 Unlike the media and intima, which are synonymic 
with smooth muscle and endothelium, respectively, the 
adventitia does not have a defined synonymic cell type. 
However, when an artery’s cross-section is stained for 
CD34, 2 concentric rings of cells corresponding to the 
intima and adventitia are revealed. The inner ring is thin, 
compact, and complete, and is undoubtedly the endothelium 
that also stains positive for CD31. The outer ring, which 
is outside of the media and thus belongs to the adventitia, 
is irregular, loose, incomplete, and distinctively CD31-. 
This population of CD34+ CD31- adventitial cells is now 
increasingly believed to be VSCs.(26,77,78)
 Therefore, the adventitia consists of a complex 
community of interacting cell types, and abundant evidence 
now indicates that a better understanding of molecular 
mechanisms for homeostasis, repair, and disease of the vessel 
wall will require a greater appreciation of the integrated role 
of the adventitia with the intimal and medial layers. This 
population of CD34+ CD31- adventitial cells was also said 
to exist in all of the human organs studied, including urinary 
bladder, testis, prostate, kidney, lung, heart, liver, and 
brain, the term ‘‘vasculogenic zone’’ to denote the CD34+ 
CD31- ring in the adventitia of human blood vessels, and 
suggested that the CD34+ CD31- cells might be progenitor 
cells for postnatal vasculogenesis. MSC-like cells residing 
in the same vasculogenic zone were shown to be CD44+ but 
CD34-.(79)
 A recent study provided strong evidence that native 
MSCs in BM lack CD44 expression.(80) Thus, equating 
the CD44+ CD34- adventitial cells with MSCs will require 
stronger evidence. In 2004, Hu et al.(24) reported the 
identification of cells that stained positive for cell markers 
Spinocerebellar Ataxia 1 (Sca1), c-kit, CD34, and for Fetal 
Liver Kinase 1 (Flk1) in the adventitia of mouse aorta. 
When transferred to the adventitial side of vein grafts in 
Apolipoprotein E (ApoE)-deficient mice, Sca1-expressing 
adventitial cells were found in atherosclerotic lesions of 
the intima. The authors thus concluded that a population of 
Figure 4. Micro-CT transaxial images of a double knockout mouse 
(LDL−/−, apoE−/−) aorta after it was injected with a radiopaque 
silicon polymer.(57) (Adapted with permission from Elsevier BV).
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vascular progenitor cells in the adventitia could differentiate 
into SMCs which contribute to atherosclerosis.(6)
 The Sca1 expression mentioned earlier in the 
adventitia has been independently confirmed in mouse aorta 
and mesenteric and femoral arteries.(25) More importantly,
Sca1+ cells immune-selected from the aortic adventitia 
were found capable of smooth muscle and endothelial 
differentiation. Moreover, when the Sca1-selected cells 
were treated with Bone Morphogenetic Protein 2 (BMP2), 
colonies formed that stained positive by alizarin red, 
suggesting osteogenic differentiation. These findings thus 
reinforced the existence of APCs.(6) Indeed, pericytes’ 
functions are more than blood flow regulation, but as 
diverse as performing vessel stabilization, vascular tone 
regulation, vessel permeability regulation, local tissue 
homeostasis maintenance, macrophage-like properties, 
immunologic defense, coagulation intervention, and control 
of the quiescent and angiogenic stages of blood vessels.
(81) Thus, with these large degrees of functional diversity 
and sophistication, how can pericytes still maintain a 
large capacity for differentiation, including the ability to 
become many different cell types with each having its own 
sophisticated functions. On the other hand, APCs are not 
known to have any specific physiological function and are, 
thus, developmentally more akin to primitive cells whose 
primary role is serving as progenitors for various specialized 
cell types. In the capillary, which lacks a defined adventitia, 
the APC equivalent still exists, as evidenced by the presence 
of the same CD34+ CD31- CD140b- SMA- cells in both the 
adventitia and the capillary.(78,82)
 Thus, it has been postulated that, within the vasculature, 
APCs could differentiate into pericytes (CD34- CD31- 
CD140b+ SMA-), ECs (CD34+ CD31+ CD140b- SMA-), and 
SMCs (CD34- CD31- CD140b- SMA+); and during tissue 
expansion or repair, APCs could also differentiate into 
tissue-specific cell types (e.g., muscle and fat).(78,82) As 
defined earlier, VSCs reside within the vessel wall and can 
differentiate into all cell types that constitute a functional 
blood vessel. They can probably also differentiate into 
specific mesenchymal cells of their native tissue, or they 
can induce the replication/differentiation of such cells via 
growth factor secretion. Consistent with these proposed 
VSC characteristics, APCs are the most likely candidates 
for being VSCs. Thus, in vitro, APCs fulfill all criteria for 
being VSCs. Meanwhile, in vivo evidence is still limited and 
will require further investigations.(6)
Vascular Stem Cells and Therapeutic Promise
Now, it is widely accepted that atherosclerosis is a chronic 
inflammatory disease.(39,83) Chronic inflammatory 
processes alter the 3-dimensional structure of the vascular 
wall (vascular modeling), leading to the atherosclerotic 
plaque formation.(84) CD34+ CD31- CD146- CD45-  cells 
residing in tunica adventitia of arteries and veins yield in 
culture multipotent progenitors functionally and antigenically 
to MSC. Coincidentally, the tunica adventitia is believed to 
play a role in vascular remodeling and be involved in the 
development of atherosclerosis.(85-88) Adventitial cells 
indeed proliferate, differentiate into myofibroblasts, and 
migrate into the inner layer of blood vessels in response 
to injury or stress.(24,89-92) CD34+ CD31- cells located 
in the ‘‘vasculogenic zone’’ of the thoracic artery, between 
the tunica media and tunica adventitia, can also give rise to 
endothelium; hence, they could represent a resident pool of 
EPCs for postnatal vasculogenesis.(26)
 The vessel wall has a substantial intrinsic capacity for 
wound repair. Under normal conditions, the artery wall in 
adult animals has very low to undetectable rates of ECs or 
SMC proliferation. When subjected to overstretch injury, 
however, proliferation rates in all layers of artery wall can 
increase more than 100-fold.(47,93) Because of its location 
between the vessel wall and the surrounding tissues in which 
the vessel is located, adventitial cells could, in principle, 
participate in tissue repair or disease processes in either the 
vessel wall itself or in surrounding nonvascular tissues.(67) 
An early event observed following many forms of arterial 
injury is adventitial inflammation and an accumulation of 
monocytes and activated macrophages in the adventitia.(94-
96) This local inflammatory response may be necessary for 
down-regulation of the ongoing adventitial niche signaling 
that maintains Sca1+ cells as progenitors, thus resulting in 
the “release” of these progenitor cells to adopt other cell 
fates.
 Direct evidence for the capability of adventitial cells 
to migrate through the media and into the intima has been 
obtained by transplanting cells onto the adventitial side of 
an artery and monitoring movement of these cells following 
arterial injury.(24,90,97,98) In addition, an intriguing 
possibility is that adventitial Sca1+ progenitor cells may 
be stimulated by arterial injury to adopt an SMC-like 
phenotype and migrate into the media and possibly into 
the intima, and thereby participate in neointimal formation.
(24,25) Development of new cell therapeutics based on 
detailed understanding of generation of VSCs holds great 
promise.
 Whereas uncertainties concerning cell lineages and 
identities remain, there is sufficient available information to 
consider a scenario in which VSCs play critical physiological 
roles in vascular development and homeostasis, as sources of 
fibrogenic cells in pathological situations, and as a possible 
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